Ced the disappointer.

The first-line standard treatment for advanced malignant pleural mesothelioma (MPM) is platinum and pemetrexed. However, there is early phase clinical evidence that anti-angiogenic agents may also be active in MPM. The phase 2 SWOG S0905 trial randomized patients with chemo-naive MPM receiving platinum/pem to +/- concurrent and maintenance cediranib (a VEGF/PDGF-inhibitor). Unfortunately, cediranib produced modest responses with significant grade 3+ toxicity. | Tsao, J Clin Oncol 2019